Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
The historical rank and industry rank for Genetics Generation Advancement's Graham Number or its related term are showing as below:
ROCO:4160'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52 Med: 2.19 Max: 31.35
Current: 2.38
During the past 13 years, the highest Price to Graham Number ratio of Genetics Generation Advancement was 31.35. The lowest was 1.52. And the median was 2.19.
ROCO:4160's Price-to-Graham-Number is ranked worse than 51.39% of 72
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.365
vs ROCO:4160: 2.38
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Genetics Generation Advancement (ROCO:4160) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Genetics Generation Advancement's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Jun. 2026 )
=
39.75
/
16.73
=
2.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Genetics Generation Advancement Graham Number Related Terms
Genetics Generation Advancement Graham Number Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement Graham Number Chart
ROCO:4160 vs TMO, DHR, IDXX: Graham Number Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Price-to-Graham-Number vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Graham Number of NT$16.73 as of Jun. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Genetics Generation Advancement and its competitors. According to the industry distribution chart, Genetics Generation Advancement ranks #37 out of 72 companies in the Medical Diagnostics & Research industry, placing it in the top 51.4%.
Is Genetics Generation Advancement's Graham Number too high?
Genetics Generation Advancement's current Graham Number is NT$16.73. Based on the distribution chart, Genetics Generation Advancement ranks #37 out of 72 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Graham Number compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #37 out of 72 companies for Graham Number. This places Genetics Generation Advancement in the lower half of its industry. The industry median Graham Number is 2.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Diagnostics & Research company?
The median Graham Number among Medical Diagnostics & Research companies is 2.37, based on 72 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Graham Number is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Graham Number is NT$16.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.25, compared to a current price of NT$39.75 — trading 25.4% below its estimated fair value. The current Graham Number is NT$16.73. Genetics Generation Advancement's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Graham Number is NT$16.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$39.75 is trading 25.4% below its estimated GF Value™ of NT$53.25.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Graham Number: NT$16.73
GF Value™: NT$53.25 vs. price of NT$39.75 (25.4% below fair value)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
72GF Score
Get the complete analysis for ROCO:4160
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
